Mark Johnson, MD
Internal Medicine · Mason City, IANPI 1013923127
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $201,350 of the $222,961 with a category attached, or 90.3%. 21 manufacturers reported payments, led by Novo Nordisk at 48.8% of the total. Among internal medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 433 payments — averaging $514.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$109K
- AstraZeneca$24K
- Sanofi-aventis U.S. LLC$23K
- Bayer$18K
- Biohaven Pharmaceuticals, Inc.$16K
- Boehringer Ingelheim$15K
- plus $17K from 15 others
What the payments were for
- Consulting fees$2,8561%
- Speaking & faculty fees$201,35090%
- Travel & lodging$11,3895%
- Food & beverage$7,1873%
- Education$1780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 129 | $108,856 |
| AstraZeneca | 47 | $24,246 |
| Sanofi-aventis U.S. LLC | 47 | $23,493 |
| Bayer | 23 | $17,826 |
| Biohaven Pharmaceuticals, Inc. | 43 | $16,057 |
| Boehringer Ingelheim | 30 | $15,235 |
| Lilly USA, LLC | 33 | $11,912 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $3,225 |
| Medtronic | 17 | $1,160 |
| Abbott | 14 | $281 |
| Insulet Corporation | 14 | $207 |
| Johnson & Johnson | 18 | $192 |
| Teva Pharmaceuticals USA, Inc. | 1 | $77 |
| Corcept Therapeutics | 2 | $66 |
| Dexcom, Inc. | 2 | $35 |
| Tandem Diabetes Care, Inc. | 2 | $22 |
| Daiichi Sankyo Inc. | 1 | $17 |
| BETA Bionics, Inc. | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
| AbbVie | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$49,904
- Ozempic$47,054
- JARDIANCE$26,578
- FARXIGA$23,675
- SOLIQUA 100/33$19,501
- NURTEC ODT$18,495
- Kerendia$17,704
- Tresiba$7,567
- DISEASE STATE$1,926
- TOUJEO$1,513
- MINIMED 780G$735
How this compares
$222,961 in reported general payments places this provider in the 95th percentile of 583 internal medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,205 | $1,336,999 |
| JardianceEmpagliflozin | 749 | $624,968 |
| TrulicityDulaglutide | 381 | $441,181 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 475 | $434,923 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 344 | $289,395 |
| MounjaroTirzepatide | 240 | $261,665 |
| FarxigaDapagliflozin Propanediol | 319 | $251,072 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 183 | $172,064 |
| Novolog FlexpenInsulin Aspart | 492 | $106,420 |
| Humalog Kwikpen U-200Insulin Lispro | 71 | $98,179 |
| Xigduo XrDapaglifloz Propaned/Metformin | 136 | $97,790 |
| Tresiba Flextouch U-100Insulin Degludec | 172 | $83,606 |
| Humalog Kwikpen U-100Insulin Lispro | 269 | $71,548 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 183 | $67,183 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 99 | $53,570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog, Novolog Mix 70-30 | $108,856 | $1,418,9801,336 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $15,235 | $935,2661,123 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $11,912 | $711,443682 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $23,493 | $434,923475 claims |
| AstraZenecaFarxiga | $24,246 | $251,072319 claims |
| Johnson & JohnsonInvokana | $192 | $23,28331 claims |
| BayerKerendia | $17,826 | $7,53412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 internal medicine providers in Iowa.
Other internal medicine in Mason City
- Adam HoffmannMason City$4K
- Jashan GillMason City$3K
- Muhammad TahirMason City$2K
- Mark CarlsonSioux City$174K
- Madalyn WalshIowa City$80K
- Alan KricsfeldCouncil Bluffs$49K
- Aziz HammoudIowa City$29K
- Matthew FryzekCouncil Bluffs$28K
- Diana Rabadi MararCouncil Bluffs$25K
- Isam MararCouncil Bluffs$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.